Recon: EMA recommends boosters targeting Omicron BA.4/5; FDA funding negotiations heat up as deadline looms
ReconMichael MezherBiologics/ biosimilars/ vaccinesBiotechnologyDiagnostics/IVDsEuropeGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/Policy